ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 128 filers reported holding ESPERION THERAPEUTICS INC NE in Q3 2023. The put-call ratio across all filers is 0.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $283,341 | -18.4% | 289,123 | +15.7% | 0.01% | -16.7% |
| Q2 2023 | $347,275 | -11.4% | 249,838 | +1.3% | 0.01% | -25.0% |
| Q1 2023 | $392,115 | -73.6% | 246,613 | +3.3% | 0.01% | -75.0% |
| Q4 2022 | $1,487,450 | -8.5% | 238,756 | -1.6% | 0.03% | -13.5% |
| Q3 2022 | $1,626,000 | -0.6% | 242,616 | -5.7% | 0.04% | +2.8% |
| Q2 2022 | $1,636,000 | +35.8% | 257,234 | -1.0% | 0.04% | +71.4% |
| Q1 2022 | $1,205,000 | -5.8% | 259,783 | +1.6% | 0.02% | -4.5% |
| Q4 2021 | $1,279,000 | -59.3% | 255,803 | -2.0% | 0.02% | -62.1% |
| Q3 2021 | $3,145,000 | -45.2% | 260,959 | -3.8% | 0.06% | -44.2% |
| Q2 2021 | $5,736,000 | -23.4% | 271,204 | +1.6% | 0.10% | -27.3% |
| Q1 2021 | $7,490,000 | -2.2% | 267,011 | -9.4% | 0.14% | -8.3% |
| Q4 2020 | $7,662,000 | -19.6% | 294,696 | +14.9% | 0.16% | -31.0% |
| Q3 2020 | $9,533,000 | -30.6% | 256,483 | -4.2% | 0.23% | -33.3% |
| Q2 2020 | $13,735,000 | +61.6% | 267,683 | -0.7% | 0.34% | +31.4% |
| Q1 2020 | $8,498,000 | -54.9% | 269,513 | -14.7% | 0.26% | -37.4% |
| Q4 2019 | $18,836,000 | +111.2% | 315,889 | +29.8% | 0.41% | +96.2% |
| Q3 2019 | $8,920,000 | +2.2% | 243,329 | +29.7% | 0.21% | +2.9% |
| Q2 2019 | $8,725,000 | +20.5% | 187,549 | +4.0% | 0.20% | +24.4% |
| Q1 2019 | $7,240,000 | -14.3% | 180,324 | -1.8% | 0.16% | -24.8% |
| Q4 2018 | $8,449,000 | -0.9% | 183,679 | -4.4% | 0.22% | +23.2% |
| Q3 2018 | $8,523,000 | -2.9% | 192,094 | -14.3% | 0.18% | -2.2% |
| Q2 2018 | $8,781,000 | -80.8% | 224,071 | -64.6% | 0.18% | -79.8% |
| Q1 2018 | $45,722,000 | +5.3% | 632,131 | -4.2% | 0.90% | +7.3% |
| Q4 2017 | $43,441,000 | +20.7% | 659,803 | -8.1% | 0.84% | +25.9% |
| Q3 2017 | $35,977,000 | +5.8% | 717,813 | -2.3% | 0.66% | +1.5% |
| Q2 2017 | $33,990,000 | +24.9% | 734,453 | -4.7% | 0.65% | +25.6% |
| Q1 2017 | $27,211,000 | +1766.3% | 770,618 | +561.6% | 0.52% | +1693.1% |
| Q4 2016 | $1,458,000 | – | 116,480 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,679,835 | $69,675,000 | 19.39% |
| Endurant Capital Management LP | 207,293 | $5,390,000 | 1.94% |
| Bellevue Group AG | 5,138,451 | $133,599,000 | 1.53% |
| Rhenman & Partners Asset Management AB | 592,225 | $15,398,000 | 1.26% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,562,869 | $40,635,000 | 0.93% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 31,434 | $817,000 | 0.62% |
| WASATCH ADVISORS LP | 3,998,010 | $103,949,000 | 0.51% |
| HAMILTON LANE ADVISORS LLC | 46,181 | $1,201,000 | 0.45% |
| Boxer Capital, LLC | 500,000 | $13,000,000 | 0.42% |
| DCF Advisers, LLC | 38,500 | $1,001,000 | 0.41% |